120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
整合生物信息学和实验验证识别CCNA2为肺腺癌中通过PI3K/AKT通路发挥作用的新型预后生物标志物和肿瘤促进因子
Authors Li JP, Zhang MY, Li R, Huo C, Qu JJ , Qu YQ
Received 1 October 2025
Accepted for publication 21 January 2026
Published 29 January 2026 Volume 2026:19 571529
DOI https://doi.org/10.2147/IJGM.S571529
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Ching-Hsien Chen
Jian-Ping Li, Meng-Yu Zhang, Rui Li, Chen Huo, Jia-Jia Qu, Yi-Qing Qu
Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, 250012, People’s Republic of China
Correspondence: Yi-Qing Qu, Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Wenhuaxi Road 107#, Jinan, 250012, People’s Republic of China, Tel +86 531 8216 9335, Fax +86 531 8296 7544, Email quyiqing@sdu.edu.cn
Purpose: To investigate the prognostic value of cell cyclin A2 (CCNA2) in lung adenocarcinoma (LUAD) and to explore its mechanisms in promoting cancer progression.
Patients and Methods: In this study, we employed an integrated strategy combining bioinformatics, clinical analysis and molecular biology to elucidate the role of CCNA2 in LUAD. First, comprehensive bioinformatics analyses were performed using public datasets. This included detecting the differential expression of CCNA2 in LUAD versus normal tissues, analyzing its correlation with patient survival and clinical characteristics, and employing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) analysis to predict the functions of CCNA2-associated genes. The relationship between CCNA2 expression and immune infiltration was further examined via the tumor immune estimation resource (TIMER) platform. The expression level of CCNA2 was also confirmed through reverse transcription-quantitative PCR and Western blotting. Additionally, the biological function of CCNA2 was evaluated by constructing an in vitro transfection model.
Results: The results of the present study indicated that CCNA2 was upregulated in LUAD tissues. Cox regression analysis revealed that CCNA2 upregulation is a independent prognostic biomarker for LUAD. Additionally, CCNA2 was markedly associated with immune cell infiltration and immune checkpoint molecules. The results of in vitro experiments confirmed that knockdown of CCNA2 significantly inhibited the proliferation, invasion and migration of H1975 and H1299 cells. Furthermore, CCNA2 was found to promote the invasion and migration of lung cancer cells through the PI3K/AKT signaling pathway.
Conclusion: The present research identified the prognostic signature and biological function of CCNA2 in LUAD, which suggested that CCNA2 may be a potential prognostic biomarker and a pivotal oncogenic driver for this disease.
Keywords: LUAD, CCNA2, predictive significance, biological function, PI3K/AKT
Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, 250012, People’s Republic of China
Correspondence: Yi-Qing Qu, Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Wenhuaxi Road 107#, Jinan, 250012, People’s Republic of China, Tel +86 531 8216 9335, Fax +86 531 8296 7544, Email quyiqing@sdu.edu.cn
Purpose: To investigate the prognostic value of cell cyclin A2 (CCNA2) in lung adenocarcinoma (LUAD) and to explore its mechanisms in promoting cancer progression.
Patients and Methods: In this study, we employed an integrated strategy combining bioinformatics, clinical analysis and molecular biology to elucidate the role of CCNA2 in LUAD. First, comprehensive bioinformatics analyses were performed using public datasets. This included detecting the differential expression of CCNA2 in LUAD versus normal tissues, analyzing its correlation with patient survival and clinical characteristics, and employing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) analysis to predict the functions of CCNA2-associated genes. The relationship between CCNA2 expression and immune infiltration was further examined via the tumor immune estimation resource (TIMER) platform. The expression level of CCNA2 was also confirmed through reverse transcription-quantitative PCR and Western blotting. Additionally, the biological function of CCNA2 was evaluated by constructing an in vitro transfection model.
Results: The results of the present study indicated that CCNA2 was upregulated in LUAD tissues. Cox regression analysis revealed that CCNA2 upregulation is a independent prognostic biomarker for LUAD. Additionally, CCNA2 was markedly associated with immune cell infiltration and immune checkpoint molecules. The results of in vitro experiments confirmed that knockdown of CCNA2 significantly inhibited the proliferation, invasion and migration of H1975 and H1299 cells. Furthermore, CCNA2 was found to promote the invasion and migration of lung cancer cells through the PI3K/AKT signaling pathway.
Conclusion: The present research identified the prognostic signature and biological function of CCNA2 in LUAD, which suggested that CCNA2 may be a potential prognostic biomarker and a pivotal oncogenic driver for this disease.
Keywords: LUAD, CCNA2, predictive significance, biological function, PI3K/AKT